NANJING, China, July 13, 2022 /PRNewswire/ — About July 13, 2022Triastek, Inc. (“Triastek”) announced a collaboration with Eli Lilly and Company (“Lilly”), a leading global pharmaceutical company, to leverage the benefits of 3D printing technology to enable targeted release and programmed medication in specific regions of the gastrointestinal tract.
According to the agreement, the project will focus on the targeted delivery of drugs to the gut. Triastek will focus on two aspects: Ffirst of all, conduct an in-depth study of excipient properties and process parameters to maintain drug stability throughout the formulation development and 3D printing process, as well as during drug release. Second, to identify a unique three-dimensionally structured dosage form design, which will enable the programmed release of drugs into specific parts of the intestine, with the aim of improving the bioavailability of orally administered drugs.
Triastek is a 3D printing technology platform company, and its pioneer MED® The technology has versatile applications in the development and manufacture of solid dosage forms. With the facilitation of this collaboration by Lilly China Innovation & Partnerships, Triastek will work with Lilly to explore new solutions for oral drug delivery.
Triastek is committed to promoting the application of 3D printing technology in the pharmaceutical field. Triastek’s 1st and 2nd products (T19 and T20) have received IND clearance from the United States Food and Drug Administration (FDA). The company also holds 158 patent applications related to 3D printing of pharmaceuticals with full patent coverage worldwide. Triastek has also established collaborations with a number of multinational pharmaceutical companies, as well as national pharmaceutical companies to provide technical solutions for the development of complex formulations.
dr. Senping Chengfounder and CEO of Triastek, said: “the collaboration between Triastek and Lilly is an excellent example of the application of MED® technology to improve oral drug delivery. We envision that the MED® Triastek’s technology can be used to solve formulation challenges leading to the development of clinically valuable products for our global partners.“
Founded in 2015, Triastek, Inc. is the world leader in 3D printing of pharmaceutical products and is a pioneer in the implementation of digital pharmaceutical solutions. Triastek’s new proprietary 3D printing technology platform encompasses dosage form design, digital pharmaceutical product development and smart manufacturing.
SOURCE Triastek, Inc.